Agios Pharmaceuticals Inc (AGIO) Shares Bought by Sei Investments Co.

Sei Investments Co. lifted its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 255.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,099 shares of the biopharmaceutical company’s stock after acquiring an additional 6,540 shares during the quarter. Sei Investments Co.’s holdings in Agios Pharmaceuticals were worth $767,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Alps Advisors Inc. boosted its stake in shares of Agios Pharmaceuticals by 11.5% in the second quarter. Alps Advisors Inc. now owns 83,297 shares of the biopharmaceutical company’s stock valued at $7,016,000 after purchasing an additional 8,580 shares during the period. Jennison Associates LLC boosted its stake in shares of Agios Pharmaceuticals by 1.7% in the second quarter. Jennison Associates LLC now owns 193,935 shares of the biopharmaceutical company’s stock valued at $16,335,000 after purchasing an additional 3,183 shares during the period. Barrett Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $253,000. First Trust Advisors LP lifted its stake in Agios Pharmaceuticals by 8.3% in the second quarter. First Trust Advisors LP now owns 731,794 shares of the biopharmaceutical company’s stock worth $61,639,000 after acquiring an additional 56,038 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Agios Pharmaceuticals by 459.8% in the second quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock worth $34,315,000 after acquiring an additional 334,617 shares during the last quarter. Hedge funds and other institutional investors own 93.63% of the company’s stock.

Shares of Agios Pharmaceuticals stock traded down $1.89 during trading on Friday, reaching $69.01. The company’s stock had a trading volume of 327,749 shares, compared to its average volume of 440,885. The stock has a market capitalization of $4.47 billion, a price-to-earnings ratio of -10.22 and a beta of 1.73. Agios Pharmaceuticals Inc has a fifty-two week low of $51.62 and a fifty-two week high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) EPS for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.43. The business had revenue of $40.40 million for the quarter, compared to analysts’ expectations of $12.47 million. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The company’s quarterly revenue was up 257.5% on a year-over-year basis. During the same period in the previous year, the company posted ($1.78) EPS. On average, equities analysts expect that Agios Pharmaceuticals Inc will post -6.11 EPS for the current year.

In other news, Director John Maraganore sold 13,555 shares of the company’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $72.75, for a total transaction of $986,126.25. Following the transaction, the director now directly owns 38,609 shares of the company’s stock, valued at approximately $2,808,804.75. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $83.07, for a total transaction of $249,210.00. Following the completion of the sale, the insider now owns 60,196 shares in the company, valued at $5,000,481.72. The disclosure for this sale can be found here. Insiders sold a total of 25,627 shares of company stock worth $1,961,796 over the last ninety days. Corporate insiders own 3.02% of the company’s stock.

AGIO has been the subject of a number of recent research reports. Cann reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Friday, July 20th. BidaskClub upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 27th. Guggenheim initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, September 17th. They issued a “neutral” rating for the company. ValuEngine downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 11th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $96.27.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Read More: Do closed-end mutual funds pay dividends?

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply